Our Pipeline

Advancing novel product candidates for
heart disease as well as inborn errors of metabolism

We are advancing a clinical stage pipeline of novel product candidates in two key areas of energy metabolism: cardiovascular disease and inborn errors of metabolism. Our lead program, IMB-101, is currently in clinical development for conditions of oxygen deprivation in the heart. The initial indications we are targeting with IMB-101 are refractory angina and heart failure. Our additional product candidates, IMB-202 and IMB-203, are designed to address the energy deficiency in patients with rare genetic mutations in mitochondrial metabolism, including those with propionic acidemia and other inborn errors of metabolism.

pFOX INHIBITION

Preclinical

Phase 1

Phase
2a | 2b

Phase 3

Anticipated Milestones

Ownership

Initiate Phase 2b clinical trial in first half of 2020

Meet with FDA to discuss regulatory pathway in 2020

MITOCHONDRIAL SUBSTRATE REPLACEMENT

Preclinical

Phase 1

Phase 2

Phase 3

Anticipated Milestones

Ownership

Initiate Phase 1/2 clinical trial in the first half of 2020

Inborn Errors of Metabolism

Initiate Phase 1 clinical trial in second half of 2020

IMB-101

A small molecule currently in Phase 1 development for the treatment of:

  • Refractory Angina
  • Heart Failure

IMB-202

An oral substrate replacement therapy designed to deliver therapeutic doses of citrate. IMB-202 is being investigated for the treatment of propionic acidemia, a rare mitochondrial disease

IMB-203

A succinate prodrug designed to deliver high doses of succinate in patients with inborn errors of metabolism